TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS


TOYOPEARL GigaCap DEAE - PUSHING THE PRODUCTIVITY OF ANION EXCHANGE STEPS

Tosoh Bioscience is introducing a new weak anion exchanger that offers a very high dynamic binding capacity while maintaining good peak resolution. Besides other applications this is of special interest for the purification of plasma proteins.

TOYOPEARL GigaCap DEAE-650 is the newest member of the renowned TOYOPEARL GigaCap series of high capacity ion exchange media. The polymeric base bead was chemically modified to provide a high number of anionic binding sites for increased resin capacity. The typical dynamic binding capacity (DBC) of over 150 g/L for bovine serum albumin exceeds the DBC of all other commercial available DEAE chromatography media. The resin was proved to be stable for more than 100 cleaning-in-place (CIP) cycles with 0.5 M NaOH. Good mass transfer kinetics enable the resin to maintain DBC at faster linear velocities and leads to a narrow elution peak. This results in smaller and more concentrated in-process pool volumes, thus reducing the amount of water and buffer needed. The high capacity and low back pressure creates opportunities for increased throughput in various anion exchange purification steps and is ideally suited for efficient plasma protein purification.

Contact:

TOSOH BIOSCIENCE GmbH
Zettachring 6 70567 Stuttgart, Germany
Tel. +49 (0)711 13257-0
Fax: +49 (0)711 13257-89

sales-marketing.tbg@tosoh.com

www.separations.eu.tosohbioscience.com/Products/ProcessMedia/ByMode/IEC/ToyopearlGigaCapDEAE-650M.htm

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here